BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28882083)

  • 1. Regulation of MAPK signaling and implications in chronic lymphocytic leukemia.
    Shukla A; Shukla V; Joshi SS
    Leuk Lymphoma; 2018 Jul; 59(7):1565-1573. PubMed ID: 28882083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
    Ten Hacken E; Burger JA
    Biochim Biophys Acta; 2016 Mar; 1863(3):401-413. PubMed ID: 26193078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL.
    Shukla A; Rai K; Shukla V; Chaturvedi NK; Bociek RG; Pirruccello SJ; Band H; Lu R; Joshi SS
    Blood; 2016 May; 127(19):2310-21. PubMed ID: 26809508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
    ten Hacken E; Burger JA
    Pharmacol Ther; 2014 Dec; 144(3):338-48. PubMed ID: 25050922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
    Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
    Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia.
    Giannoni P; Cutrona G; Totero D
    Curr Mol Med; 2017; 17(1):24-33. PubMed ID: 28231754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia.
    Cuesta-Mateos C; López-Giral S; Alfonso-Pérez M; de Soria VG; Loscertales J; Guasch-Vidal S; Beltrán AE; Zapata JM; Muñoz-Calleja C
    Exp Hematol; 2010 Sep; 38(9):756-64, 764.e1-4. PubMed ID: 20488224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia.
    Patton JT; Woyach JA
    Semin Hematol; 2024 Apr; 61(2):100-108. PubMed ID: 38749798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Therapy in Chronic Lymphocytic Leukemia.
    Kipps TJ; Choi MY
    Cancer J; 2019; 25(6):378-385. PubMed ID: 31764118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
    Feng G; Wang X
    Leuk Lymphoma; 2014 Dec; 55(12):2699-705. PubMed ID: 24547708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
    Robak T; Robak P
    Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Signaling Pathways in Chronic Lymphocytic Leukemia.
    Muggen AF; Singh SP; Hendriks RW; Langerak AW
    Curr Cancer Drug Targets; 2016; 16(8):669-688. PubMed ID: 27055580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape.
    Burger JA
    Curr Opin Oncol; 2012 Nov; 24(6):643-9. PubMed ID: 22960555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors.
    Mato A; Jauhari S; Schuster SJ
    Am J Hematol; 2015 Jul; 90(7):657-64. PubMed ID: 25808792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic Lymphocytic Leukemia: Disease Biology.
    Koehrer S; Burger JA
    Acta Haematol; 2024; 147(1):8-21. PubMed ID: 37717577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
    Hill RJ; Lou Y; Tan SL
    Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.
    Arnason JE; Brown JR
    Curr Oncol Rep; 2017 Sep; 19(9):61. PubMed ID: 28755313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy.
    Ramsay AD; Rodriguez-Justo M
    Br J Haematol; 2013 Jul; 162(1):15-24. PubMed ID: 23617880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling.
    Lorenzo-Herrero S; Sordo-Bahamonde C; Bretones G; Payer ÁR; González-Rodríguez AP; González-García E; Pérez-Escuredo J; Villa-Álvarez M; Núñez LE; Morís F; Gonzalez S; López-Soto A
    Front Immunol; 2019; 10():2455. PubMed ID: 31681329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.